Finerenone Prescriptions in the US (2021-2024) by Physician Specialty: Analysis of Use and Potential in the CKM Space
Jelwan, Y.; Cao, T.; Yao, Z.; Burka, S.; Erhabor, J.; Berning, P.; Dzaye, O.; Blaha, M. J.
Show abstract
IntroductionFinerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has demonstrated greater receptor selectivity and fewer side effects compared to older mineralocorticoid receptor antagonists. Clinical trials support its efficacy in reducing kidney disease progression, cardiovascular events, and heart failure outcomes across various patient populations, however, anecdotally, the drug appears infrequently utilized in clinical practice. MethodsA serial, cross-sectional analysis of IQVIAs National Prescription Audit (NPA), which covers over 70% of U.S. outpatient prescription activity, was conducted from July 2021 to December 2024 to examine finerenone prescribing trends focusing on cardiologists and nephrologists. For added context, prescription rates of finerenone were compared to those of two other medications with related mechanisms or indications commonly used in Cardiovascular-Kidney-Metabolic (CKM) syndrome, spironolactone and empagliflozin. Prescribing trends were correlated with total search activity using Google Trends. ResultsWe found that finerenone was prescribed at a rate of 30,180 prescriptions/month in December 2022, increasing to 45,420 in December 2023, and 60,756 prescriptions/month in December 2024. This modest increase correlated with changes in Google search activity, with mild inflections after the release of major clinical trial data. The ratio of total prescriptions from nephrologists (15.81 prescriptions per nephrologist) to cardiologists (0.70 prescriptions per cardiologist) in 2024 was approximately 23:1. The proportion of finerenone prescriptions to other CKM therapies remained low, with finerenone prescriptions numerically representing 3.0% of empagliflozin prescriptions and 2.6% of spironolactone prescriptions in 2024. ConclusionThe adoption of finerenone has been modest, especially among cardiologists compared to nephrologists, and lags behind other CKM therapies. However, recent trends show an upward shift in its use that correlates with public interest related to clinical trial results.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of An Impedance Cardiography Guided Treatment Strategy to Improve Blood Pressure Control in A Real-World Setting: Results from A Pilot Pragmatic Clinical Trial 93%
- The Impact of COVID-19 Pandemic on Cardiology Services 92%
- Multispecialty multidisciplinary input into comorbidities in heart failure reduces hospitalisation and clinic attendance 92%
Similar papers in this journal
- Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patients 92%
- Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom 92%
- A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model 90%
Similar papers in this journal
- Association of Cardiologist Clinic Visits with Cardiovascular Primary Prevention Outcomes Among People with HIV from Underrepresented Racial and Ethnic Groups in the Southern United States 93%
- Progression of Carotid Intima-Media Thickness in Children of the Cardiovascular Comorbidity in Children with Chronic Kidney Disease Study (4C Study) – Risk Factors and Impact of Blood Pressure Dynamics 93%
- Long-term Outcomes of Peripheral Artery Disease In Veterans: Analysis of the PEripheral ARtery Disease Long-term Survival Study (PEARLS) 92%
Similar papers in this journal
- Multiple Biomarkers to Predict Major Adverse Cardiovascular Events in Patients With Coronary Chronic Total Occlusions 92%
- The Association Between the Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study 92%
- Risk of Cardiovascular Events after Covid-19: a double-cohort study 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.